BEIJING, Jan. 8, 2016 /PRNewswire/ -- Today, Xi'an Janssen Pharmaceutical Co., Ltd. announced the launch of a new therapeutic drug for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in China - Zeke ® (abiraterone acetate tablets), in order to help patients prolong their lives and improve their quality of life. Metastatic castration-resistant prostate cancer has always been a difficulty in the treatment of advanced prostate cancer, and the average life expectancy of patients is usually less than 2 years [1]. In addition to traditional endocrine therapy and chemotherapy, there is a lack of effective treatment methods in China. Zeke ® is an androgen biosynthetic enzyme inhibitor, and its launch will provide a new treatment modality for patients with metastatic castration-resistant prostate cancer.
"Choose Ze, Another Tomorrow" Launching Ceremony of Zeco® China Launch Press Conference, from left: Mr. Avery Ince, Vice President of Xi'an Janssen Pharmaceutical Co., Ltd., Ms. Zheng Lei of Xi'an Janssen Pharmaceutical Co., Ltd., Kaiser, President of Xi'an Janssen Pharmaceutical Co., Ltd. Mr. Ye Zhangqun, Professor of Hubei Institute of Urology, Professor Li Hanzhong, Department of Urology, Peking Union Medical College Hospital, Professor Xie Liping, Department of Urology, First Affiliated Hospital of Zhejiang University School of Medicine, Professor Ji Zhigang, Department of Urology, Peking Union Medical College Hospital
Cesar Rodriguez, President of Xi'an Janssen Pharmaceutical Co., Ltd. ) Speech
"Choose Ze, Another Tomorrow" Press Conference for the Launch of Zeke® in China
Prostate cancer is the second most common cancer among men worldwide. In the past decade, the incidence of prostate cancer has increased rapidly in China, and has become the sixth most common malignant tumor among men [2]. Data show that the incidence rate of prostate cancer in Beijing increased from 5.53/100,000 in 2001 to 16.62/100,000 in 2010 [3]. The incidence rate of prostate cancer in Shanghai has increased more than 10 times in the past 20 years [4]. Professor Ye Zhangqun from the Hubei Institute of Urology emphasized, “Due to lifestyle changes, population aging, and the popularization of early screening, the number of prostate cancer patients in our country is increasing year by year, and big cities have become the ‘hardest hit areas.’ In our country, people over 60 years old Elderly men are at high risk for prostate cancer [5], and the older they are, the higher the risk of the disease [6]. However, the Chinese public has a low level of awareness of prostate cancer and cannot correctly understand the high-risk factors for prostate cancer and conduct self-examination. The public awareness of symptoms, early screening and treatment options is less than 30% [7]. "
Prostate cancer is also described as a "silent killer". It is not easy to detect in the early stage. The disease is usually diagnosed in the advanced stage, and the main symptom is blood in the urine. , dysuria and bone pain. Professor Li Hanzhong from the Department of Urology at Peking Union Medical College Hospital said, "Prostate cancer is a hormone-dependent malignant tumor, and androgens play an important role in the occurrence and development of prostate cancer. Androgen deprivation therapy is the main treatment for advanced prostate cancer in China. However, it does not block all pathways of androgen synthesis. For example, the tumor itself can also produce androgens. 90% of patients who receive androgen deprivation therapy will develop castration-resistant prostate cancer after 18-24 months [ 8], or even metastasize to other organs other than the prostate, such as bones, becoming metastatic castration-resistant prostate cancer. "
Professor Xie Liping, Department of Urology, First Affiliated Hospital of Zhejiang University School of Medicine, pointed out: "The data show that androgen levels are further reduced. , the patient's survival period can be further prolonged [9]. Zeke ® can block androgen synthesis in the testicles, adrenal glands and the tumor itself. It is recommended by many domestic and foreign prostate cancer treatment guidelines. It is marketed in China as androgen deprivation. New options and new hope for patients with metastatic castration-resistant prostate cancer after treatment failure"
Results from two international multicenter clinical trials involving 2,283 patients with metastatic castration-resistant prostate cancer. The safety and effectiveness of Zeke® have been confirmed [10], [11]. Avery Ince, Vice President of Medical Affairs of Xi'an Janssen Pharmaceutical Co., Ltd., said: "Zeco® is a once-daily oral tablet used in combination with prednisone to treat metastatic castration-resistant prostate cancer.Clinical trial studies have shown that patients with metastatic castration-resistant prostate cancer who received chemotherapy before treatment were treated with Zeke ®, the median overall survival was extended to 34.7 months and the use of opioids for cancer pain was delayed to 33.4 months. months [12], delaying chemotherapy by 25.2 months [13]; patients with metastatic castration-resistant prostate cancer who received chemotherapy were treated with Zeke ® , the median overall survival was extended to 15.8 months, and the risk of death was reduced. 20%[14]. Therefore, Zeke ® can effectively prolong the overall survival of patients and significantly improve the quality of life. "
Cesar Rodriguez, President of Xi'an Janssen Pharmaceutical Co., Ltd., said: "Xi'an Janssen has always been committed to caring for the health of patients and their families. By introducing the innovative product Zeke ®, we can better meet the treatment needs of patients and help alleviate the pain caused by the disease. Developing a new drug is only one part of our battle against disease. Another important part is doing everything we can to make this treatment available to patients who desperately need it. In the future, we will continue to meet China's growing medical and health needs through innovation and cooperation. "
At present, Zeke ® has entered more than 100 cities including Beijing, Shanghai, and Guangzhou. At the same time, the China Primary Health Care Foundation has launched the "Ze Bei Life-Prostate Cancer Patient Assistance Project" to provide low-income Medicago ® (abiraterone acetate tablets) pharmaceutical aid is available to patients with metastatic castration-resistant prostate cancer.
Zeco® has been approved in 100 countries and is widely used in more than 230,000 prostate cancer patients worldwide. Cancer patients.
